Latest Tumor antigen Stories
A pioneering approach to imaging breast cancer in mice has revealed new clues about why the human immune system often fails to attack tumors and keep cancer in check.
In a review article posted online March 16 in Cell, the researchers say that refinements and modifications of monoclonal antibody drugs -- several of which have already revolutionized the care of breast and colon cancer --are now being tested in most tumor types.
Researchers from the Perelman School of Medicine at the University of Pennsylvania report this month in Cancer Research a universal approach to personalized cancer therapy based on T cells.
At the most basic level, the immune system must distinguish self from non-self, that is, it must discriminate between the molecular signatures of invading pathogens (non-self antigens) and cellular constituents that usually pose no risk to health (self-antigens).
At first it sounds like good news: The body's own immune system gets active in almost every cancer – however, not necessarily for the benefit of the patient.
Mayo Clinic investigators cured well-established prostate tumors in mice using a human vaccine with no apparent side effects.
- The horn of a unicorn considered as a medical or pharmacological ingredient.
- A winged horse with a single horn on its head; a winged unicorn.